MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
HER2/EGFR in Cancer Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,303 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,303 works in the cohort · of 4,299,418page 16 of 27

Labels cover 3 of 1,303 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,303 of 1,303 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

afffundunlabeled
A novel method of cell embedding for tissue microarrays
Magdalena Zietarska, Jason Madore, Jean‐Simon Diallo, Nathalie Delvoye, Fred Saad, Diane Provencher +1 more
2010· letter· en· Histopathology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
affno abstractunlabeled
1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03
David Planchard, Julie R. Brahmer, James Chih‐Hsin Yang, Hye Ryun Kim, R.K. Li, J-Y. Han +6 more
2023· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
affunlabeled
HER2 Genetic Heterogeneity in Gastric Cancer
Ann Treacy, Jason Karamchandani, Catherine Streutker, Andrea Grin
2015· article· en· Applied immunohistochemistry & molecular morphology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations
affno abstractunlabeled
Letter to the Editor
Wedad Hanna, Elizabeth Hammond, Clive R. Taylor, David J. Dabbs, Frédérique Penault‐Llorca, Kenneth J. Bloom +2 more
2008· letter· en· Modern Pathology· Medicine
machine prediction:candidate · insufficient_payloadconsensus · none
6
citations
fundno affunlabeled
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).
Toshinari Yamashita, Shigehira Saji, Toshimi Takano, Yoichi Naito, Michiko Tsuneizumi, Akiyo Yoshimura +14 more
2024· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
6
citations

How this was built: Screen · Findings · About